We aimed to compare human menopausal gonadotropin (hMG) and recombinantfollicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development ofovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS)treated with in vitro fertilization (IVF). This evidence concerns the gene BRD2 and polycystic ovary syndrome.